News

The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. Potential SMA Treatment granted orphan medicinal product designation by the European Medicines Agency (EMA)

    Potential SMA Treatment granted orphan medicinal product designation by the European Medicines Agency

    Cytokinetics announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation to reldesemtiv for the potential treatment of SMA. Reldesemtiv is a drug that has been shown, in the laboratory, to increase the force generated by skeletal muscle and which delays the onset and extent of muscle fatigue. This could be beneficial to people living with SMA or certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.

    An Orphan medicinal product designation is granted by the European Commission, to medicines intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating disease affecting fewer than 5 in 10,000 people in the European Union, or for which it is unlikely that the costs associated with the development and commercialisation of the medicine would be recovered by expected sales under normal market conditions. The designation offers potential incentives, which may include a ten-year period of EU marketing exclusivity from the date of marketing authorisation, EU-funded research, protocol assistance and fee reductions.

    Find out more